Activate Biology. Protect Future. Smart wearable for personalized healing
Get Started
The Next Frontier in Digital Therapeutics
HOMEOSTAT is a breakthrough research initiative that introduces a novel class of wearable therapeutics designed to stimulate the body’s intrinsic healing systems. Through real-time, non-invasive mechanical stimulation delivered via intelligent motorised bands, HOMEOSTAT activates cytokine modulation, vascular protection, and autonomic rebalancing—unlocking a high-impact, drug-free approach to improving systemic resilience.
This wearable platform integrates non-pneumatic, motorised occlusion bands, PPG (photoplethysmography) sensors, and an adaptive mobile app that precisely controls stimulation cycles based on the user’s own physiology. The result is a safe, scalable, and comfortable device that transitions smoothly from clinical research to practical health interventions.
While HOMEOSTAT is currently under evaluation for EU Pathfinder funding, it reflects a fully conceptualised and tested innovation framework—and we are excited to share our vision with stakeholders, partners, and the world.
TRACTION: Patents & Research Papers
Qloud Technologies already holds two patents related to RIPC devices and logic, providing a solid foundation for future IP development and commercial scaling.
Intelligent Stimulation. Biological Activation. HOMEOSTAT delivers controlled, short-duration compression to the limbs. These cycles mimic physiological stress signals, such as ischemia-reperfusion, which trigger the body’s homeostatic defense mechanisms.
Unlike oscillometric or pneumatic cuff devices, HOMEOSTAT features no pumps, no sizing issues, and no clinical setup—just wearable, app-based autonomy.
The Technology
From Stimulus to Adaptation: An Integrated System
HOMEOSTAT merges next-generation wearable design with digital physiology
Motorized, non-pneumatic bands – quiet and precise
PPG sensors – track perfusion and vascular tone
Bluetooth microcontroller – connects hardware and app
The HOMEOSTAT project will validate its system through three clinical demonstrators hosted at leading institutions:
1) MGH (USA): Maps cytokine response; focuses on safety, comfort, biomarkers, and endothelial function.
2) AUTH (Greece): Tests BFR for rehab; evaluates strength, lactate, safety, and usability.
3) UPO (Italy): Explores cardioprotection pre-CT-PCI; targets biomarkers, integration, and comfort.
Each study targets a unique therapeutic angle—prehabilitation, recovery, or procedural resilience—anchored by real-world performance indicators and user feedback.
Next Planned Research
HOMEOSTAT in Cancer Care: A Universal Homeostasis Approach
Support Across Cancer Stages: Maintains physiological balance from diagnosis to recovery.
Real-Time Monitoring: Detects early health decline via continuous vitals tracking.
Prehabilitation: Boosts readiness with personalized training and stress relief.
Treatment Safety: Prevents heart, kidney, and liver toxicity during therapy.
Recovery Assistance: Guides rehab through recovery tracking.
Smart Interface: Connects body and therapy to maintain balance.
New Oncology Approach: Focuses on homeostasis for better outcomes.
Benefits
01
Drug-free modulation of inflammation and vascular repair
02
Enhances physiological recovery post-exercise, post-surgery, or post-procedure
03
Safe, precise, and easy to use, with no sizing limitationse
04
PPG-guided control allows real-time personalisation
05
Usable in hospitals, gyms, or at home
06
Scalable to cardio, cancer, and performance care.
Consortium
World-Class Collaboration Meets Human-Centric Innovation HOMEOSTAT is being developed by a high-impact European and international consortium, combining academic excellence, clinical depth, and technology leadership.